Janssen Pharmaceutica N.V., Belgium — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
JNJ-64042056The purpose of this study is to assess whether JNJ-64042056 affects the spread and build up of tau (a protein in brain) when compared with placebo, using brain scan (tau PET) to determine results from specific areas of the brain.	Alzheimer	Phase 2	À vérifier	United States, Australia, Belgium, France, Germany, Japan, Spain, Sweden, …	À vérifier
JNJ-64042056The purpose of this study is to assess whether JNJ-64042056 affects the spread and build up of tau (a protein in brain) when compared with placebo, using brain scan (tau PET) to determine results from specific areas of the brain.	Alzheimer	Phase 2	À vérifier	United States, Australia, Belgium, France, Germany, Japan, Spain, Sweden, United Kingdom	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
JNJ-64042056	Alzheimer	Phase 2	NCT06544616	Reτain — A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease	ACTIVE_NOT_RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.